Biological Dynamics and the OHSU Knight Cancer Institute Announce Cancer Diagnostic Research Collaboration

SAN DIEGO and PORTLAND, Oregon, September 28, 2017 -- Biological Dynamics, Inc., a developer of innovative oncology-focused molecular diagnostic products, and the Knight Cancer Institute at Oregon Health & Science University (OHSU), a national leader in translational oncology research, have initiated a collaboration to advance early cancer detection. The research will take place at the OHSU Cancer Early Detection Advanced Research (CEDAR) Center in Portland, with Biological Dynamics providing CEDAR Center researchers with early technology access to its NanoVerita™ and ExoVerita™ platforms.

"The ability to directly access critical biomarkers, such as cell-free DNA and exosomes in blood, plasma, and serum is extremely valuable for early cancer detection,” said Raj Krishnan, Ph.D. founder and chief executive officer of Biological Dynamics. “When cancer is caught early, patient outcomes are vastly improved. Biological Dynamics’ disruptive technology and expertise in nanoparticle isolation, combined with the world-renowned team from CEDAR, will accelerate the development of novel diagnostic solutions to help millions of people live longer and better lives.”

Biological Dynamics research portfolio is built upon the novel AC Electrokinetics (ACE) technology platform that also powers the company’s clinical diagnostic program. The NanoVerita™ lab-on-a-chip system delivers a simple sample-to-answer workflow for isolation and detection of macromolecular targets (e.g. cell-free DNA). The newly introduced ExoVerita™ system is optimized for the isolation and analysis of extracellular vesicles. The system enables direct isolation and analysis of DNA, exosomes and proteins from biological fluids, by interacting with nanoparticles via a novel electrical interface. The revolutionary dilution-free workflow addresses fundamental limitations of many current approaches, delivering a robust solution to liquid biopsy, therapeutic response monitoring, and ultimately, early disease detection.

"At CEDAR, our mission is to find better ways to detect cancer earlier for quicker therapeutic intervention to save lives. By collaborating with industry partners, we can access emerging technologies that can accelerate our research efforts," said Paul Spellman, Ph.D., Knight Cancer Institute CEDAR Center Co-Director. "We were impressed with the ability of Biological Dynamics’ lab-on-chip platforms to quickly and simultaneously isolate DNA, RNA, and exosomal biomarkers as well as scale as the project progresses to clinical validation. We will work with the team at Biological Dynamics to research new methods to detect and eliminate lethal cancers early."

About the OHSU Knight Cancer Institute

The Knight Cancer Institute at Oregon Health & Science University is a pioneer in personalized cancer medicine. The institute's director, Brian Druker, M.D., helped prove it was possible to shut down cells that enable cancer to grow without harming healthy ones. This breakthrough has helped make once-fatal forms of the disease manageable and ushered in a new generation of targeted cancer therapies. The OHSU Knight Cancer Institute is the only National Cancer Institute-designated Comprehensive Cancer Center between Sacramento and Seattle—an honor earned only by the nation's top cancer centers. It offers the latest treatments and technologies as well as hundreds of research studies and clinical trials. For more information, visit

About Biological Dynamics

Biological Dynamics, Inc. is a San Diego based molecular diagnostic company with a primary focus on oncology. Biological Dynamics’ novel lab-on-a-chip platform uses the company’s proprietary ACE technology to isolate and analyze cfDNA, exosomes and other nanoparticles and macromolecules directly from biofluids. The company is deploying its universal ACE platform in three strategic areas: treatment response in oncology, nanoparticle-based research, and point-of-care smartphone-enabled molecular diagnostics. The NanoVerita™ system and ExoVerita™ instrument have not been cleared or approved by the U.S. FDA. For more information, visit  


Media Contact: Jessica Yingling, Ph.D., Little Dog Communications Inc., +1.858.3448091